Covid-19 trial firm Synairgen is up 955%. Here’s what I’d do now

Active growth investors seeking investments in biotech companies working on Covid-19 solutions might want to consider Synairgen. But is it a good buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AIM-listed biotech firm Synairgen (LSE:SNG) has been on a rocket ride since markets crashed in March 2020. In fact, the share price is nearly 1,000% higher than it was at the beginning of January.

The real kicker came on 18 March. On this day, the FTSE 100, S&P 500, Dow Jones and practically every other world stock market index plummeted. But SNG shot up because of a release that detailed how the company’s wholly-owned SNG001 treatment would be trialled on coronavirus patients.

SNG001 is an inhaled version of the antiviral protein interferon-beta-1a. In its injectable form, under the brand name Avonex, the drug is produced by NASDAQ-listed Biogen and used to treat symptoms of multiple sclerosis. The Synairgen formulation is converted into a fine spray and delivered to the lungs in much the same way as asthma medication.

Covid-19 in 2020

Looking at a short-term chart of the Synairgen share price I can see very many peaks and troughs. This says to me that the market is unsure of its true fair value.

It’s only natural in the middle of a global pandemic for investors to consider buying companies with potential Covid-19 treatments.

The medical world is racing to find treatments and vaccines for the disease caused by the SARS-CoV-2 virus. Clearly there is a newly-urgent need to assess new treatments for the respiratory illness that can occur as a result.

But I would warn that such investments come with significant strings attached.

At a market cap of £75m Synairgen is about the smallest-sized company I’d be happy to trade shares in. At this level, liquidity is likely to be poor. This means there might not always be sellers available when you want to buy, or buyers when you want to sell.

The good, the bad, the ugly

The Synairgen board of directors is stacked full of pharma heavyweights. These include non-exec director Dr Bruce Campbell, a visiting professor in pharmacology at King’s College London, and chief scientific officer Dr Phillip Monk, a respiratory disease specialist.

I’ve written on other Covid-19 related companies recently, like Novacyt and Omega Diagnostics. The first of these has seen its share price grow by 2,750% since the start of January.

But investing in unproven firms is a dangerous game for long-term investors. For every success there are many more companies that cannot follow through on their promises. And the smaller the firm, the more issues it will have with scale. If governments suddenly want 10m of their treatments, there would be huge manufacturing and supply chain challenges.

The process of bringing drugs to market is also long, slow and expensive. Costs are high for medical research companies as they have to invest significant sums in clinical trials and stringent regulatory requirements.

So when we look back through the balance sheets for Synairgen over the last five years we can see uneven revenue and profits. For example, 2017’s annual revenue was £5.03m, with £1.63m in pre-tax profit. In 2018 revenues were £100,000 with a pre-tax loss of £4.1m.

I’d say an investment would be fine for seasoned traders and those who know their biotech inside and out.

For retirees and novices, I would urge more caution. If you intend to sit on an investment for 10 years, you could be left holding shares at a loss when everyone else has scarpered.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tom Rodgers has no position in the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »

Investing Articles

I’m expecting my Phoenix Group shares to give me a total return of 25% in 2025!

Phoenix Group shares have had a difficult few months but that doesn't worry Harvey Jones. He loves their 10%+ yield…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

14.5bn reasons why I think the Legal & General share price is at least 11% undervalued

According to our writer, the Legal & General share price doesn’t appear to reflect the underlying profitability of the business. 

Read more »